Another of today's winners in the health-care space is Myriad Genetics (MYGN -3.49%), up 11% today after Medicare reimbursement cuts were announced. Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a result.
In this video, Motley Fool health-care analyst David Williamson discusses the Medicare cuts and the fact that they were still extremely severe, despite not being as severe as once feared. He also gives investors a few reasons not to love Myriad Genetics, despite the boost it got today from the market's expectations game.
